SecBot SecBot
8-K ·Filed Nov 2, 2026

NBIX

NEUROCRINE BIOSCIENCES INC
BULLISH
Impact 6/10
Horizonweeks Processed14d 10h ago SEC0000914475-26-000053
8-K Item 2.02: Earnings release
Actionable Insight ▲ Bullish

The raised INGREZZA guidance and strong VYKAT XR launch validate the Soleno acquisition thesis. Watch for the December 15 R&D Day for updates on Phase 3 readouts for osavampator (MDD) and direclidine (schizophrenia), which are key pipeline catalysts for 2027.

DirectionBullish
Confidencehigh
Horizonweeks

Drugs in focus

NBIX drug pipeline →

direclidine

● Neutral Named in this 8-K
Impact
Phase
Phase 3
Time to market
If Phase 3 trials succeed, a potential FDA submission could occur in 2028, with approval possible in 2029 at the earliest, assuming topline data reads out in 2027 and a standard ~12-month review cycle.
Next catalyst
None dated

What to watchThe next hard catalyst is Phase 3 topline data for direclidine in schizophrenia, expected in 2027 (timeline per Neurocrine's Q3 2026 earnings call on Nov 2, 2026). Positive data would validate direclidine as a potential competitor to the recently approved Cobenfy (KarXT) in the muscarinic agonist class; negative or mixed data would significantly hurt the stock given direclidine is one of Neurocrine's two late-stage pipeline assets.

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$164.85
T+0 close · Nov 2, 2026 · via day close
Latest settled
+2.60%
T+5 · $169.14 · next T+20 in 15d
Vs SPY
+3.19%
α at T+5
Latest observation
+1.68%
T+8 · FF3 residual α
  1. T+0 · Nov 3 $164.85entry
  2. T+1 · 13d ago +0.73%α −0.92% · $166.05
  3. T+5 · 7d ago +2.60%α +3.19% · $169.14
  4. T+9 · todayOpen
  5. T+20 · in 15d Pending
  6. T+60 · in 3mo Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Neurocrine Biosciences reported Q3 2026 total revenue of $1.123B, up 41% YoY, with net product sales exceeding $1B for the first time. INGREZZA net sales guidance was raised to $2.9B-$2.925B from $2.825B-$2.875B. Non-GAAP EPS of $3.29 beat the $2.75 consensus, and revenue of $1.123B beat the $1.04B consensus.

Key Financial Metrics

EPS (Adj.)
$3.29
est $2.75 · +19.6% · GAAP: $1.96
Revenue
$1.1B
est $1.0B · +8.0% · +41.2% YoY
Rating
strong beat
Guidance
$2.9B-$2.925B (INGREZZA only)
raised

Key Facts

  • Q3 2026 total revenue $1.123B, up 41% YoY from $795M
  • INGREZZA net product sales $801M, up 17% YoY
  • CRENESSITY net product sales $211M, up 115% YoY
  • VYKAT XR net product sales $107M (first contribution from Soleno acquisition)
  • INGREZZA full-year 2026 guidance raised to $2.9B-$2.925B
  • Non-GAAP EPS $3.29 vs consensus $2.75 (beat)
  • GAAP EPS $1.96 vs $2.04 in prior year (decline due to acquisition-related costs and equity investment losses)
  • Cash and marketable securities $790M at quarter end, down from $2.543B at Dec 2025 due to Soleno acquisition

Financial Impact

Revenue beat consensus by ~$83M (8%); Non-GAAP EPS beat consensus by $0.54 (19.6%)

revenueepsguidance

Segment Breakdown

SegmentRevenueGrowth
INGREZZA$801.0M+17.0%
CRENESSITY$211.0M+115.0%
VYKAT XR$107.0MNot reported

Risk Factors

  • GAAP net income declined YoY due to acquisition-related costs and $52M equity investment loss
  • Cash balance significantly reduced from $2.543B to $790M following Soleno acquisition
  • Integration of Soleno and VYKAT XR commercial execution still in early stages

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
86% bullish (37 analysts)

Investment Themes

Documents Analyzed

This report is based on 6 SEC documents filed with EDGAR.

DocumentAccession Number
8-K Filing (Primary)0000914475-26-000053
Document: nbix-20261102.htm0000914475-26-000053
Document: 0000914475-26-000053-index-headers.html0000914475-26-000053
Document: 0000914475-26-000053-index.html0000914475-26-000053
Document: 0000914475-26-000053.txt0000914475-26-000053
8-K Data (Synthetic)0000914475-26-000053

Track record

30 reports on NBIX

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+20. Best: +27.40% at T+60 after the Apr 6, 2026 report. 4 of 4 went positive at some point.

Filters
  1. Nov 10, 20266d ago 144 Neutral 2/10 Entry $174.41 Now $165.31 −5.22% settles Dec 10
  2. Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
  3. Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
  4. Nov 10, 20267d ago PTAB Trial Neutral 3/10 Entry $169.14 Now $165.31 −2.26% settles Dec 9
  5. Nov 2, 202614d ago Press Release Bullish 6/10 No price data
  6. Nov 2, 202614d ago 144 Neutral 2/10 Entry $164.85 Now $165.31 +0.28% settles Dec 2
  7. Nov 2, 202614d ago 8-K Bullish 6/10 Viewing Entry $164.85 Now $165.31 +0.28% settles Dec 2
  8. Oct 30, 202617d ago 144 Neutral 1/10 Entry $145.35 Now $165.31 +13.73% settles Dec 1
  9. Oct 30, 202617d ago SC 13G Neutral 3/10 Entry $146.10 Now $165.31 +13.15% settles Nov 30
  10. Oct 27, 202620d ago Institutional Cluster Mixed 3/10 Entry $145.53 Now $165.31 +13.59% settles Nov 25
Showing 10 of 30

US Market Status

Market Closed · Opens in 7h 2m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 2, 2026